IL4 and lymphedema: Similarly, treatment of mice with neutralizing antibodies against IL4 or IL13, cytokines necessary for differentiation of naïve Th cells to Th2 phenotype, not only prevented the development of lymphedema in preclinical mouse models but also treated lymphedema once it was established [14].